Andrew Lam joined Ally Bridge Group in 2021 and is a Managing Director, Head of Biotech, for the private equity strategy focused on investments in biotech. Before joining Ally Bridge Group, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals. Before that, Andrew was a Vice President, Healthcare Investment Banking at Jefferies and an Equity Research Associate at BMO Capital and Canaccord Genuity. Andrew began his career at several biotechnology companies, including Celgene and Shire. Andrew holds a PharmD from Long Island University and received an MBA from Drexel University.